Dr David Fuller is an internationally experienced biopharmaceutical executive and physician. He has more than 30 years of R&D experience, spanning large, mid and small cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation.
Most recently Dr Fuller was the Senior Vice President of Clinical Development in the Oncology Business Unit at Syneos Health Clinical Solutions. Prior to this he was a Director at Linear Clinical Research, Chairman of Dimerix Bioscience, CMO/COO at Trident Clinical Research, CMO at Arana Therapeutics, and Vice-President Clinical at Genzyme Europe.
In addition to his role at Race Oncology, Dr Fuller also serves as Chairman for EpiAxis Therapeutics, a privately owned epigenetic therapeutic and diagnostic company, and is a Non-Executive Director of the ASX- listed biotech company, AdAlta (ASX: 1AD).
Dr Fuller holds a Bachelor of Medicine / Bachelor of Surgery degree, and a Bachelor of Pharmacy (First Class Honours in Pharmacology), both from University of Sydney. He is also a Member of the American Society Clinical Oncology (ASCO).
To view Dr David Fuller’s LinkedIn profile, please click here.